AstriVax
Latest round
- Seed
Last raised
- Aug 2022
Total raised
- $10M
Investors
- 8
About AstriVax
Based in Belgium, and founded in 2022, AstriVax operates as a vaccine technology company. The company was founded by its CEO, Hanne Callewaert, Johan Neyts, and Kai Dallmeier. AstriVax offers a PLLAV platform, which is a plasmid-launched live attenuated virus technology that engages in the production of thermostable infectious vaccines. The company’s portfolio develops prophylactic vaccines and therapeutic vaccines through its pipeline technology. These vaccines can be used to protect against several illnesses, including chronic hepatitis B, rabies, and yellow fever.
Who invested in AstriVax
8 investors across 1 round
See all investors in AstriVax
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Aug 16, 2022
Amount
$10M
Investors
Questions about AstriVax
Who invested in AstriVax?
AstriVax has 8 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has AstriVax raised?
AstriVax has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did AstriVax last raise money?
AstriVax's most recent round on record is a Seed, in Aug 2022.
What does AstriVax do?
Based in Belgium, and founded in 2022, AstriVax operates as a vaccine technology company.
Where is AstriVax headquartered?
AstriVax is headquartered in Heverlee, Belgium.
Which VCs invest in companies like AstriVax?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at AstriVax's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like AstriVax? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.